

# SAFETY DATA SHEET

Cat# 2419-1, -5, Dalcetrapib

SDS DATE: Sep 27, 2013

## SECTION 1: PRODUCT AND COMPANY IDENTIFICATION

**PRODUCT NAME:** Dalcetrapib  
**PRODUCT CODES:** Cat# 2419-1, -5  
**MANUFACTURER:** BioVision, Inc.  
**ADDRESS:** 155 S. Milpitas Boulevard, Milpitas, CA 95035  
**EMERGENCY PHONE:** 858-373-8066  
**CHEMTREC PHONE:**  
**OTHER CALLS:** 408-493-1800  
**FAX PHONE:** 408-493-1801

## SECTION 2: COMPOSITION/INFORMATION ON INGREDIENTS

Product Name/Chemical Name	Description	Volume	Safety Information
Dalcetrapib	Solid	2419-1: 1 mg 2419-5: 5 mg	See below

## SECTION 3: HAZARDS IDENTIFICATION

Components	CAS Number	EC-No.	Molecular Weight	Chemical Formula
Dalcetrapib	211513-37-0	--	389.59	C <sub>23</sub> H <sub>35</sub> NO <sub>2</sub> S

### Dalcetrapib:

#### Emergency Overview:

**OSHA Hazards:** No known OSHA hazards

**GHS Classification:** Not a dangerous substance according to GHS

#### GHS Label elements, including precautionary statements

**Pictogram:** none

**Signal word:** none

**Hazard statement(s):** none

**Precautionary statement(s):** none

#### HMIS Classification

**Health hazard:** 0

**Flammability:** 0

**Physical hazards:** 0

#### NFPA Rating

**Health Hazard:** 0

**Fire:** 0

**Reactivity Hazard:** 0

#### Potential Health Effects

**Inhalation:** May be harmful if inhaled. May cause respiratory tract irritation.

**Skin:** May be harmful if absorbed through skin. May cause skin irritation.

**Eyes:** May cause eye irritation.

**Ingestion:** May be harmful if swallowed.

## SECTION 4: FIRST AID MEASURES

**If inhaled:** If breathed in, move person into fresh air. If not breathing, give artificial respiration.

**In case of skin contact:** Wash off with soap and plenty of water.

**In case of eye contact:** Flush eyes with water as a precaution.

**If swallowed:** Never give anything by mouth to an unconscious person. Rinse mouth with water.

## 5: FIRE-FIGHTING MEASURES

**Condition of flammability:** Not flammable or combustible.

**Suitable extinguishing media:** Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

**Special protective equipment for fire fighters:** Wear self-contained breathing apparatus for firefighting if necessary.

**Hazardous combustion products:** Hazardous decomposition products formed under fire conditions— see section 10.

## SECTION 6: ACCIDENTAL RELEASE MEASURES

**Personal precautions:** Avoid dust formation. Avoid breathing vapors, mist, or gas.

**Environmental precautions:** Do not let product enter drains.

**Methods for cleaning up:** Sweep up and shovel. Keep in suitable, closed containers for disposal.

# SAFETY DATA SHEET

Cat# 2419-1, -5, Dalcetrapib

SDS DATE: Sep 27, 2013

## SECTION 7: HANDLING AND STORAGE

### Precautions for safe handling

Provide appropriate exhaust ventilation at places where dust is formed.

### Conditions for safe storage

Keep container tightly closed in a dry and well-ventilated place.

Recommended storage temperature: -20 °C.

## SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

Contains no substances with occupational exposure limit values.

### Personal protective equipment

#### Respiratory protection

Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

#### Hand protection

Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.

#### Eye protection

Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166 (EU).

#### Skin and body protection

Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and to the specific workplace. The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.

#### Hygiene measures

General industrial hygiene practice.

## SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

Property	Dalcetrapib
Appearance:	Crystalline solid
pH:	No data available
Water Solubility:	No data available
Other Solubility:	DMSO (>50 mg/ml) or EtOH (>50 mg/ml)
Boiling Point (°C):	No data available
Melting Point (°C):	No data available
Flash Point (°C):	No data available
Ignition Temperature (°C):	No data available
Density:	No data available

## SECTION 10: STABILITY AND REACTIVITY

Property	Dalcetrapib
Chemical stability	Stable under recommended storage conditions
Conditions to avoid:	No data available
Materials to avoid:	No data available
Hazardous decomposition products:	Carbon oxides, nitrogen oxides, sulfur oxides

## SECTION 11: TOXICOLOGICAL INFORMATION

### Dalcetrapib:

**Acute toxicity:** No data available

**Skin corrosion/irritation:** no data available

**Serious eye damage/eye irritation:** no data available

**Respiratory or skin sensitization:** no data available

**Germ cell mutagenicity:** no data available

### Carcinogenicity:

IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by ACGIH.

NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA.

**Reproductive toxicity:** no data available

# SAFETY DATA SHEET

Cat# 2419-1, -5, Dalcetrapib

SDS DATE: Sep 27, 2013

**Teratogenicity:** no data available

**Specific target organ toxicity – single exposure (GHS):** no data available

**Specific target organ toxicity – repeated exposure (GHS):** no data available

**Aspiration hazard:** no data available

**Potential Health Effects**

**Inhalation:** May be harmful if inhaled. May cause respiratory tract irritation.

**Skin:** May be harmful if absorbed through skin. May cause skin irritation.

**Eyes:** May cause eye irritation.

**Ingestion:** May be harmful if swallowed.

**Signs and Symptoms of Exposure:** To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.

**Synergistic effects:** no data available

**Additional information:** RTECS: not available

---

## SECTION 12: ECOLOGICAL INFORMATION

---

**Dalcetrapib:**

**Persistence and degradability:** no data available

**Toxicity:** no data available

**Bioaccumulative potential:** no data available

**Mobility in soil:** no data available

**PBT and vPvB assessment:** no data available

**Other adverse effects:** no data available

---

## SECTION 13: DISPOSAL CONSIDERATIONS

---

**Product:** Observe all federal, state, and local environmental regulations.

**Contaminated packaging:** Dispose of as unused product.

---

## SECTION 14: TRANSPORT INFORMATION

---

**Dalcetrapib:**

**DOT (US):** Not dangerous goods.

**IMDG:** Not dangerous goods.

**IATA:** Not dangerous goods.

---

## SECTION 15: REGULATORY INFORMATION

---

**Dalcetrapib:**

**OSHA Hazards:** No known OSHA hazards

**SARA 302 Components:** SARA 302: No chemical in this material are subject to the reporting requirements of SARA Title III, Section 302.

**SARA 313 Components:** SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title II, Section 313.

**SARA 311/312 Hazards:** No SARA Hazards

**Massachusetts Right To Know Components:** No components are subject to the Massachusetts Right to Know Act.

**Pennsylvania Right To Know Components:** No components are subject to the Pennsylvania Right to Know Act.

**New Jersey Right To Know Components:** No components are subject to the New Jersey Right to Know Act.

**California Prop. 65 Components:** This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other reproductive harm.

**EU regulations**

Component	Risk Phrases	Safety Phrases
Dalcetrapib	--	--

---

## SECTION 16: OTHER INFORMATION

---

**DISCLAIMER:**

The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. BioVision, Inc., shall not be held liable for any damage resulting from handling or from contact with the above product. See reverse side of invoice or packing slip for additional terms and conditions of sale.